The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)
NCT ID: NCT00409721
Last Updated: 2011-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
42 participants
INTERVENTIONAL
2007-03-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
NCT00469456
Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
NCT00857649
The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
NCT00255086
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
NCT00322153
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
NCT00097916
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Memantine Low Dose
Memantine
Memantine High Dose
Memantine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Memantine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 - 80 years,
* ALS symptoms for no more than 3 years,
* FVC greater than or equal to 60% predicted,
* Riluzole naïve or have been on a stable dose of Riluzole for at least 2 months,
* Patients must have the ability to attend monthly study visits in Edmonton or Calgary, Alberta
Exclusion Criteria
* Female patients who are breastfeeding
* Use of concurrent investigational drugs,
* Patient unlikely to comply with study requirements
* Poor adherence to study protocol during run-in phase
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALS Association
OTHER
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Alberta
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ming Chan, MD
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Sanjay Kalra, MD
Role: PRINCIPAL_INVESTIGATOR
University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Calgary ALS Neuromuscular Clinic
Calgary, Alberta, Canada
University of Alberta ALS Clinic
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
ALS Association of America (ALSA)
ALS Society of Alberta
ALS Society of Canada
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EB2006ALS
Identifier Type: -
Identifier Source: secondary_id
1204
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.